CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Sirolimusdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00697112
NCT00697112N/ACompleted
CompareCT.gov

Surveillance Registry Of Sirolimus Use In Recipients Of Kidney Allograft From Expanded Criteria Donors (ECD)

Pfizer·observational·Posted Jun 13, 2008·Updated Jan 22, 2014

In Brief

An observational study evaluating Sirolimus for Renal Transplantation. Completed, enrolled 53 participants across 8 sites.

Detailed Summary

The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice. The primary objective is to identify the current criteria/reasons to use sirolimus as base therapy in this selected population and define and understand the emerging patterns of immunosuppressive treatment with sirolimus.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplantation
CountriesArgentina
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 13, 2008
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.1 years ago

Interventions

Sirolimusdrug

Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.